Regadenoson is a purine nucleoside. Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008. Regadenoson is an Adenosine Receptor Agonist. The mechanism of action of regadenoson is as an Adenosine Receptor Agonist. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lexiscan, Rapiscan and regadenosonum. Its PubChem CID is 219024.
Regadenoson
| CAS No | 313348-27-5 |
|---|---|
| Molecular Formula | C15H18N8O5 |
| Molecular Weight | 390.35 g/mol |
| Synonyms | 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Regadenoson is a purine nucleoside. Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining.
The listed CAS number is 313348-27-5.
The listed molecular formula is C15H18N8O5.
The listed molecular weight is 390.35 g/mol.
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide.
The source lists Lexiscan, Rapiscan and regadenosonum.